Detalhe da pesquisa
1.
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Haematologica
; 108(6): 1500-1514, 2023 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36226489
2.
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
Ann Hematol
; 100(6): 1485-1496, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33787984
3.
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
Haematologica
; 103(10): 1642-1653, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29773601
4.
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
Res Sq
; 2023 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36865133
5.
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Leukemia
; 37(6): 1379-1383, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37085610